Evidence map›Paper›PMID 35178738›Full record

ArticleAnnals of neurology2022

Imaging Net Retrograde Axonal Transport In Vivo: A Physiological Biomarker.

Pin-Tsun Justin Lee, Zachary Kennedy, Yuzhen Wang, Yimeng Lu, Carolina Cefaliello, Özgün Uyan, Chun-Qing Song, Bruno Miguel da Cruz Godinho, Zuoshang Xu, Mary Rusckowski and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Pin-Tsun Justin Lee *Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0002-3444-9696
Zachary Kennedy *Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Yuzhen WangDepartment of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Yimeng LuVIR Biotechnology, San Francisco, CA, USA.
Carolina CefalielloDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0002-9117-6719
Özgün UyanDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Chun-Qing SongRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Bruno Miguel da Cruz GodinhoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Zuoshang XuDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Mary RusckowskiDepartment of Radiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Wen XueRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Robert H BrownDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0001-6062-1528
University of Massachusetts Chan Medical School · USVIR Biotechnology (United States) · US

Funding

University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALSR01NS118145 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XU, ZUOSHANG · 2021 to 2025
$2.4M
An in vivo approach to understanding mutant PFN1 toxicity on motor neuronsR01NS101895 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XU, ZUOSHANG · 2017 to 2021
$1.8M
Silencing C9or72 with rAAV Mediated RNAiR01NS088689 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BROWN, ROBERT H., MUELLER, CHRISTIAN · 2014 to 2017
$1.6M
NCATS NIH HHS UL1 TR001453NIH HHS 5R01NS101895NIH HHS RO1-NS088689NIH HHS UL1-TR001453NINDS NIH HHS R01 NS088689NINDS NIH HHS R01 NS101895NINDS NIH HHS R01 NS118145
6 · The paper itself

Abstract

objectiveThe objective of this study is to develop a novel method for monitoring the integrity of motor neurons in vivo by quantifying net retrograde axonal transport.

methodsThe method uses single photon emission computed tomography to quantify retrograde transport to spinal cord of tetanus toxin fragment C (

resultsThis technique defines a quantitative profile of net retrograde axonal transport of TTC in living mice. The profile is distinctly abnormal in transgenic SOD1

interpretationThis assay of net retrograde axonal transport has broad potential clinical applications and should be particularly valuable as a physiological biomarker that permits early detection of benefit from potential therapies for motor neuron diseases. ANN NEUROL 2022;91:716-729.

Indexed as

Amyotrophic Lateral SclerosisAxonal TransportAnimalsBiomarkersDisease Models, AnimalHumansMiceMice, TransgenicProfilinsSpinal CordSuperoxide DismutaseSuperoxide Dismutase-1Tetanus ToxoidBiomarkersPFN1 protein, humanProfilinsSuperoxide DismutaseSuperoxide Dismutase-1Tetanus Toxoid

Identifiers

PMID35178738
PMCPMC9313858
OpenAlexW4213219342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.